Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Migraine
Interventions
Rimegepant, Rizatriptan Benzoate
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Interventions
rimegepant 75 mg ODT, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
33
States / cities
La Mesa, California • Panorama City, California • Roseville, California + 24 more
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Mobile, Alabama • Glendale, Arizona • Rogers, Arkansas + 44 more
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
115
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Conditions
Migraine, Episodic Migraine, Phonophobia, Photophobia
Interventions
Rimegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Phoenix, Arizona • Hawthorne, California • North Hollywood, California + 15 more
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Rimegepant, Placebo, Sumatriptan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more
Conditions
Migraine, Episodic Migraine
Interventions
Galcanezumab, Rimegepant, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
77
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tempe, Arizona + 71 more
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
93
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 86 more
Conditions
Migraine
Interventions
Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
30
States / cities
Tempe, Arizona • Colton, California • Los Angeles, California + 27 more
Conditions
Temporomandibular Disorders (TMD)
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Phoenix, Arizona • Hollywood, Florida • Miami, Florida + 17 more
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more
Completed Phase 3 Interventional Results available

Trial in Adult Subjects With Acute Migraines

NCT03461757
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
69
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 61 more
Conditions
Migraine, Migraine Disease, Migraine in Adults, Migraine Headache, Acute Migraine, Migraine Without Aura, Migraine With Aura
Interventions
Rimegepant, Zavegepant
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Pain
Interventions
aspirin and ketamine, Nurtec (Rimegepant)
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Not yet recruiting Phase 2 Interventional

Rimegepant For Endometriosis Pain

NCT07795125
Conditions
Endometriosis, Endometriosis-related Pain
Interventions
Rimegepant 75 MG, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tempe, Arizona + 45 more
Completed Phase 2Phase 3 Interventional Results available

Open Label Safety Study in Acute Treatment of Migraine

NCT03266588
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
98
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 86 more
Completed Phase 2 Interventional Results available

Rimegepant in Moderate Plaque-type Psoriasis

NCT04629950
Conditions
Psoriasis
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York
Conditions
Menstrual Migraine
Interventions
Rimegepant, Placebo Comparator, Standard of Care
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
723 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Canoga Park, California + 25 more
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Canoga Park, California • Fresno, California • Los Angeles, California + 14 more
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Conditions
Migraine Headaches
Interventions
Rimegepant, Zavegepant
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Stamford, Connecticut • Lake City, Florida + 20 more
Completed Phase 2 Interventional Results available

Comparison of Rimegepant and Placebo for Pain in IBS

NCT06221111
Conditions
Irritable Bowel Syndrome
Interventions
Rimegepant 75 MG [Nurtec]
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota